Locations:
Search IconSearch

Ophthalmology

22-EYE-3438365 CQD-Fluid volatility in nAMD-Ehlers

Exudative Stability Key to Anti-VEGF Outcome in nAMD

Advanced OCT features may help individualize treatment intervals

22-EYE-3438364 CQD _ OCT-based imaging biomarkers650x450

Unlocking Precision Medicine in RVO: When Anti-VEGF Therapy Isn’t Effective

Intraretinal fluid volumes and other features detectable with OCT may help predict treatment response

23-EYE-3521610 CQD-Time to resolution of DME-Talcott-650×450
February 8, 2023/Diabetes & Endocrinology

Diabetic Macular Edema Can Take 1-2 Years to Resolve in Patients Despite Aggressive Treatment

Greater central subfield thickness and better visual acuity at baseline are associated with longer time to resolution

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The Featured Image for the post
September 22, 2022/Ophthalmology/News & Insight

Unlocking the Potential of OCT: From Imaging to Biomarker Discovery

Innovative work earns ASRS and Macula Society awards for Justis P. Ehlers, MD

22-EYE-3066210 CQD-Losartan for corneal fibrosis-Wilson-hero

Hypertension Drug Losartan Reverses Scarring and Restores Vision After Cornea Damage

Studies indicate dramatic results when used topically with or without corticosteroids

22-EYE-3141638 CQD-EYP-1901 with vorolanib for maintenance of nAMD

DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD

53% of participants didn’t need anti-VEGF for six months or longer

22-EYE-2953384-CQD-Case study on pat with ocular migraines-str-Bajic

Case Study: When Ocular Migraine Symptoms Indicate Impending Stroke

Subtle but important distinctions for ophthalmologists

BackPage 4 of 22Next

Advertisement

Ad